Merdury Biopharmaceutical Income Statement

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	-	4.96	1.03	2.68	-
Revenue Growth (YoY)	-	380.44%	-61.46%	-	-
Cost of Revenue	-	0.78	0.44	1.51	-
Gross Profit	-	4.18	0.59	1.17	-
Selling, General & Admin	24.37	25.57	24.91	16.66	2.48
Research & Development	44.18	32.66	21.37	15.41	2.82
Operating Expenses	68.55	58.23	46.28	32.07	5.3
Operating Income	-68.55	-54.04	-45.69	-30.9	-5.3
Interest Expense	-0.9	-0.8	-0.71	-0.4	-0.01
Interest & Investment Income	3.2	4.11	3.07	0.33	0
Currency Exchange Gain (Loss)	-	-	-	-0.06	-
Other Non Operating Income (Expenses)	-0.93	0.21	-0.48	-0.22	-
Pretax Income	-67.17	-50.53	-43.82	-31.25	-5.31
Income Tax Expense	0.06	0.04	-	-	-
Net Income	-67.23	-50.57	-43.82	-31.25	-5.31
Net Income to Common	-67.23	-50.57	-43.82	-31.25	-5.31
Shares Outstanding (Basic)	420	421	398	376	277
Shares Outstanding (Diluted)	420	421	398	376	277
Shares Change (YoY)	-0.29%	5.79%	5.83%	36.09%	165.94%
EPS (Basic)	-0.16	-0.12	-0.11	-0.08	-0.02
EPS (Diluted)	-0.16	-0.12	-0.11	-0.08	-0.02
Free Cash Flow	-57.72	-44.73	-55.07	-94.35	-11.77
Free Cash Flow Per Share	-0.14	-0.11	-0.14	-0.25	-0.04
Gross Margin	-	84.30%	57.31%	43.73%	-
Operating Margin	-	-1088.90%	-4423.04%	-1152.91%	-
Profit Margin	-	-1018.90%	-4241.63%	-1166.05%	-
Free Cash Flow Margin	-	-901.17%	-5331.17%	-3520.60%	-
EBITDA	-56.91	-46.59	-41.62	-29.15	-4.73
D&A For EBITDA	11.64	7.45	4.07	1.75	0.57
EBIT	-68.55	-54.04	-45.69	-30.9	-5.3

Source: S&P Global Market Intelligence. Standard template. Financial Sources.